Description:

E5103 Adverse Event Form (CTCAE v3) NCT00433511 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=22B14F38-EFAA-6454-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=22B14F38-EFAA-6454-E044-0003BA3F9857

Keywords:
Versions (5) ▾
  1. 8/26/12
  2. 1/8/15
  3. 1/9/15
  4. 1/9/15
  5. 7/8/15
Uploaded on:

July 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

E5103 Adverse Event Form (CTCAE v3) NCT00433511

Details

INSTRUCTIONS: Complete this form at the end of each cycle (1 cycle = 3 weeks), and at required follow-ups if specified by the Long-Term Follow-Up Form (to report late adverse events).

ECOG clinical trial administrative data
Patient demographics
Data amendment
Reporting Period
On Treatment Report Period (STEP 2 - ARM D ONLY)
6 more items in the detailed view.
Off Treatment Reporting Period
Off Treatment Report Period
Adverse Events
Were adverse events assessed during this report period (cycle)
I. METABOLIC - LABS
CTC Adverse Event Term
32 more items in the detailed view.
CTC AE Attribution Code
Action taken for this AE for Chemotherapy
Action taken for this AE for Bevacizumab (/placebo)
II. NON-HEMATOLOGIC
III. NON-HEMATOLOGIC (GRADE 2-5)
CTC Adverse Event Short Name (Specify site for each event)
IV. Other Adverse Events (GRADE 3-5)
V. INFECTIONS
Comments
Back to the top of the page 

Similar models